» Articles » PMID: 30952501

A Social Justice Perspective on Access to Human Rabies Vaccines

Overview
Journal Vaccine
Date 2019 Apr 7
PMID 30952501
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Rabies kills tens of thousands of people every year despite being entirely vaccine preventable. Key global health actors have launched a country-driven plan to achieve zero human deaths from dog-mediated rabies by 2030 worldwide. This partnership has recently been strengthened by Gavi, the Vaccine Alliance's decision to invest in human rabies vaccines for post-exposure prophylaxis (PEP). While nation states are key to rabies elimination, the importance of Gavi's role cannot be understated. Unlike any other actor, Gavi can directly address an otherwise intractable market failure in the inadequate supply of rabies PEP. In this commentary, we employ the Capabilities Approach to identify the barriers to PEP access that lead to this market failure and, as a result, unnecessary deaths and suffering. We show the role that Gavi can play in reducing exposure of PEP supply to market forces as a matter of social justice, and hence redress the inequity underlying human rabies deaths.

Citing Articles

Molecular characterisation of human rabies in Tanzania and Kenya: a case series report and phylogenetic investigation.

Jaswant G, Campbell K, Czupryna A, Mwatondo A, Ogoti B, Embregts C Infect Dis Poverty. 2024; 13(1):79.

PMID: 39468631 PMC: 11514914. DOI: 10.1186/s40249-024-01245-w.


Rabies post-exposure prophylaxis delivery to ensure treatment efficacy and increase compliance.

Nadal D, Bote K, Masthi R, Narayana A, Ross Y, Wallace R IJID One Health. 2023; 1:100006.

PMID: 38152594 PMC: 10752235. DOI: 10.1016/j.ijidoh.2023.100006.


Comparative Evaluation of Intradermal -- Intramuscular Pre-Exposure Prophylactic Vaccination against Rabies in Cattle.

Gopalaiah S, Appaiah K, Isloor S, Lakshman D, Thimmaiah R, Rao S Vaccines (Basel). 2023; 11(5).

PMID: 37242989 PMC: 10220582. DOI: 10.3390/vaccines11050885.


Impact of the switch from four to three intradermal rabies post-exposure prophylaxis sessions in patients bitten by dogs: A cost-consequence analysis from the patients' perspective.

Le Bras A, Zarca K, Peng Y, Chan M, Durand-Zaleski I One Health. 2022; 15:100408.

PMID: 36277111 PMC: 9582412. DOI: 10.1016/j.onehlt.2022.100408.


Rabies Elimination in Rural Kenya: Need for Improved Availability of Human Vaccines, Awareness and Knowledge on Rabies and Its Management Among Healthcare Workers.

Chuchu V, Kitala P, Bichanga P, Ksee D, Muturi M, Mwatondo A Front Public Health. 2022; 10:769898.

PMID: 35356016 PMC: 8960031. DOI: 10.3389/fpubh.2022.769898.


References
1.
Li A, Sreenivasan N, Siddiqi U, Tahmina S, Penjor K, Sovann L . Descriptive assessment of rabies post-exposure prophylaxis procurement, distribution, monitoring, and reporting in four Asian countries: Bangladesh, Bhutan, Cambodia, and Sri Lanka, 2017-2018. Vaccine. 2018; 37 Suppl 1:A14-A19. PMC: 6702106. DOI: 10.1016/j.vaccine.2018.10.011. View

2.
Dye C . Expanded health systems for sustainable development. Science. 2018; 359(6382):1337-1339. DOI: 10.1126/science.aaq1081. View

3.
Mindekem R, Lechenne M, Naissengar K, Oussiguere A, Kebkiba B, Moto D . Cost Description and Comparative Cost Efficiency of Post-Exposure Prophylaxis and Canine Mass Vaccination against Rabies in N'Djamena, Chad. Front Vet Sci. 2017; 4:38. PMC: 5376597. DOI: 10.3389/fvets.2017.00038. View

4.
Hampson K, Abela-Ridder B, Bharti O, Knopf L, Lechenne M, Mindekem R . Modelling to inform prophylaxis regimens to prevent human rabies. Vaccine. 2018; 37 Suppl 1:A166-A173. PMC: 7612382. DOI: 10.1016/j.vaccine.2018.11.010. View

5.
Waithaka D, Tsofa B, Barasa E . Evaluating healthcare priority setting at the meso level: A thematic review of empirical literature. Wellcome Open Res. 2018; 3:2. PMC: 5814743. DOI: 10.12688/wellcomeopenres.13393.2. View